Anti-CD9 Antibody, clone Z9.1

25.42 kDa calculated

CD9 antigen (UniProt: P21926; also known as 5H9 antigen; Cell growth-inhibiting gene 2 protein; Leukocyte antigen MIC3; Motility-related protein; MRP-1; Tetraspanin-29; Tspan-29; p24) is encoded by the CD9 (also known as MIC3, TSPAN29; IG2) gene (Gene ID: 928) in human. CD9 is a multi-pass membrane glycoprotein of the tetraspanin (TM4SF) family. It is expressed in a variety of hematopoietic and epithelial cells. It displays strong expression in platelets where it mediates platelet activation and aggregation upon binding to monoclonal antibodies. CD9 induces cell-cell adhesion, platelet aggregation, and B cell development and is shown to associate with CD63, CD81, CD82, and CD36 and to bind to beta-1 integrins. CD9 activation of platelets is reported to be mediated by the Fc y RII (CD32) molecule. Downregulation of CD9 correlates with tumor progression in some forms of cancer. It can hamper metastasis formation by inhibiting integrin-mediated motility. Lower expression of CD9 are associated with weaker matrix adhesion and diffuse tumor cell growth in vitro.

Intact LoVo colorectal carcinoma cells.

Immunohistochemistry Analysis: A 1:1,000 dilution from a representative lot detected CD9 in human tonsil, human breast cancer, and human skin tissues.

Flow Cytometry Analysis: A 1:1,000 dilution from a representative lot detected CD9 in human PBMCs.
human tonsil, human breast cancer, human liver cancer, human skin

This mouse monoclonal Anti-CD9 antibody, clone Z9.1, Cat. No. MABT914, is validated for use in ELISA, Flow Cytometry, Immunohistochemistry (Paraffin), and Western Blotting for the detection of CD9.

Clone Z9.1 detects CD9 in its native, non-reduced form, in CD-9 positive cells amongst human PBMCs.

Format: Purified

Evaluated by Immunohistochemistry in human human liver cancer tissue.

Immunohistochemistry Analysis: A 1:1000 dilution of this antibody detected CD9 in human liver cancer tissue.

Concentration: Please refer to lot specific datasheet.